These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tertiary lymphoid structures in anticancer immunity. Teillaud JL; Houel A; Panouillot M; Riffard C; Dieu-Nosjean MC Nat Rev Cancer; 2024 Sep; 24(9):629-646. PubMed ID: 39117919 [TBL] [Abstract][Full Text] [Related]
5. Mature tertiary lymphoid structures: important contributors to anti-tumor immune efficacy. Bao X; Lin X; Xie M; Yao J; Song J; Ma X; Zhang X; Zhang Y; Liu Y; Han W; Liang Y; Hu H; Xu L; Xue X Front Immunol; 2024; 15():1413067. PubMed ID: 39026670 [TBL] [Abstract][Full Text] [Related]
6. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation. Domblides C; Rochefort J; Riffard C; Panouillot M; Lescaille G; Teillaud JL; Mateo V; Dieu-Nosjean MC Front Immunol; 2021; 12():698604. PubMed ID: 34276690 [TBL] [Abstract][Full Text] [Related]
7. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies. Trüb M; Zippelius A Front Immunol; 2021; 12():674565. PubMed ID: 34054861 [TBL] [Abstract][Full Text] [Related]
8. Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy. Langouo Fontsa M; Padonou F; Willard-Gallo K Expert Rev Clin Immunol; 2024 Aug; 20(8):839-847. PubMed ID: 39007892 [TBL] [Abstract][Full Text] [Related]
10. Macrophages and tertiary lymphoid structures as indicators of prognosis and therapeutic response in cancer patients. Niu L; Chen T; Yang A; Yan X; Jin F; Zheng A; Song X Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189125. PubMed ID: 38851437 [TBL] [Abstract][Full Text] [Related]
12. Investigating Tumor-Associated Tertiary Lymphoid Structures in Murine Lung Adenocarcinoma. Connolly KA; Nader M; Joshi N Methods Mol Biol; 2018; 1845():259-273. PubMed ID: 30141018 [TBL] [Abstract][Full Text] [Related]
13. Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. Tang H; Zhu M; Qiao J; Fu YX Cell Mol Immunol; 2017 Oct; 14(10):809-818. PubMed ID: 28413217 [TBL] [Abstract][Full Text] [Related]
14. STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development. Filderman JN; Appleman M; Chelvanambi M; Taylor JL; Storkus WJ Front Immunol; 2021; 12():690105. PubMed ID: 34054879 [TBL] [Abstract][Full Text] [Related]
15. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. N J; J T; Sl N; Gt B Oncoimmunology; 2021 Mar; 10(1):1900508. PubMed ID: 33854820 [TBL] [Abstract][Full Text] [Related]
16. Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application. Zhang Y; Xu M; Ren Y; Ba Y; Liu S; Zuo A; Xu H; Weng S; Han X; Liu Z Mol Cancer; 2024 Apr; 23(1):75. PubMed ID: 38582847 [TBL] [Abstract][Full Text] [Related]
17. Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy. Aoyama S; Nakagawa R; Mulé JJ; Mailloux AW Front Immunol; 2021; 12():675538. PubMed ID: 34054863 [TBL] [Abstract][Full Text] [Related]
18. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation. Salem D; Chelvanambi M; Storkus WJ; Fecek RJ Front Immunol; 2021; 12():629519. PubMed ID: 33746966 [TBL] [Abstract][Full Text] [Related]
19. Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures. Omotesho QA; Escamilla A; Pérez-Ruiz E; Frecha CA; Rueda-Domínguez A; Barragán I Front Immunol; 2024; 15():1348156. PubMed ID: 38333212 [TBL] [Abstract][Full Text] [Related]
20. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers. Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]